SCHEMBL6008635

SCHEMBL6008635

Cc1ccc(C(NCC(F)CS(=O)(=O)O)C(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 1/20 0.40
KEAP1 Q14145 6/20 0.39
NFE2L2 Q16236 6/20 0.39
ACHE P22303 2/20 0.33
GBA1 P04062 1/20 0.33
BCHE P06276 1/20 0.33
ALDH1A1 P00352 3/20 0.33
STAT3 P40763 1/20 0.33
TSHR P16473 1/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
LMNA P02545 2/20 0.31
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
ADRB3 P13945 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6008622 0.89 CA1 (0.39) ALDH1A1CA1CA2CA7CA9
SCHEMBL5504083 0.78 KEAP1 (0.36) GRIA4KEAP1NFE2L2ACHEALDH1A1
SCHEMBL6009060 0.75 KEAP1 (0.37) GRIA4KEAP1NFE2L2ACHEBCHE
SCHEMBL5503665 0.71 NR3C1 (0.41) ALDH1A1ADRB3
SCHEMBL5503668 0.69 CASR (0.39) ADRB2ADRB1ADRB3SMN1; SMN2
SCHEMBL5505984 0.68 SIGMAR1 (0.49) TSHRADRB2
SCHEMBL6008633 0.68 KCNA5 (0.40) ALDH1A1TSHRLMNA
SCHEMBL6009992 0.67 HTT (0.35) ALDH1A1CA1CA2LMNAADRB2
SCHEMBL6033150 0.65 GABBR2 (0.42) GRIA4ACHEGBA1BCHEALDH1A1
SCHEMBL17995187 0.64 KEAP1 (0.39) KEAP1NFE2L2ACHEALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR GRIA4 3357/4885KEAP1 1179/4885NFE2L2 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.